Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to evaluate the feasibility of using CSJ148 to prevent congenital human cytomegalovirus (HCMV) in pregnant women with primary HCMV infection.


Clinical Trial Description

This is a randomized, patient, investigator and sponsor blinded, placebo-controlled study in pregnant women with primary HCMV infection. The study has three periods: (I) screening (II) double-blinded placebo-controlled treatment and (III) post-delivery follow-up of women and neonates/infants. Pregnant women with confirmed primary HCMV infection will participate in periods I and II. Mothers and neonates/infants born to mothers enrolled in the study will participate in period III. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03369912
Study type Interventional
Source Novartis
Contact
Status Withdrawn
Phase Phase 2
Start date October 23, 2018
Completion date November 15, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT01113359 - The Link Between Human Cytomegalovirus (HCMV) and Hypertension N/A